Calidi Biotherapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Calidi Biotherapeutics, Inc. (CLDI) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$733.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$275.00K, a 215.55% decline year-over-year.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$458.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$808.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $264.00K.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$1.99M.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$1.85M, a 245.41% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $1.27M, a 28.17% decline from fiscal 2022.
- Calidi Biotherapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $1.77M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$733.00K 10-Q · filed 2026-08-13 | -$1.54M derived: sum of 3 quarters · filed 2026-08-13 | -$1.28M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$458.00K 10-Q · filed 2026-05-14 | -$1.27M derived: sum of 2 quarters · filed 2026-05-14 | -$1.00M derived: sum of 3 quarters · filed 2026-05-14 | -$764.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$808.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$544.00K derived: sum of 2 quarters · filed 2026-03-27 | -$306.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.99M 10-K · filed 2026-03-27 |
| 2025-09-30 | $264.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $502.00K derived: sum of 2 quarters · filed 2026-08-13 | -$1.19M 10-Q · filed 2025-11-13 | -$1.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.45M 10-Q · filed 2026-08-13 | -$2.02M derived: sum of 3 quarters · filed 2026-08-13 | -$2.21M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.69M 10-Q · filed 2026-05-14 | -$2.26M derived: sum of 2 quarters · filed 2026-05-14 | -$2.45M derived: sum of 3 quarters · filed 2026-05-14 | -$3.15M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$569.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$759.00K derived: sum of 2 quarters · filed 2026-03-27 | -$1.47M derived: sum of 3 quarters · filed 2026-03-27 | -$1.85M 10-K · filed 2026-03-27 |
| 2024-09-30 | -$190.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$897.00K derived: sum of 2 quarters · filed 2025-11-13 | -$1.28M 10-Q · filed 2025-11-13 | -$707.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$707.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$1.09M 10-Q · filed 2025-08-08 | -$517.00K derived: sum of 3 quarters · filed 2025-08-08 | -$1.31M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$388.00K 10-Q · filed 2025-05-14 | $190.00K derived: sum of 2 quarters · filed 2025-05-14 | -$601.00K derived: sum of 3 quarters · filed 2025-05-14 | $651.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $578.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$213.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.04M derived: sum of 3 quarters · filed 2025-03-31 | $1.27M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$791.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $461.00K derived: sum of 2 quarters · filed 2024-11-12 | $697.00K 10-Q · filed 2024-11-12 | $474.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.49M 10-Q · filed 2024-08-13 | $1.26M derived: sum of 3 quarters · filed 2024-08-13 | |
| 2023-03-31 | $236.00K 10-Q · filed 2024-05-14 | $13.00K derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $1.77M 10-K · filed 2024-03-15 | ||
| 2022-09-30 | $2.00M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |